Sustainability Report

Overview

The report describes SK Biopharmaceuticals' first full-year operating profit in 2024 and KRW 547.6 billion in total revenue, driven mainly by Cenobamate. It highlights the full-scale launch of the radiopharmaceutical therapy business, AI-enabled drug discovery, and expanded global partnerships. Sustainability management is based on a double materiality assessment, Board oversight, and a 2040 net-zero roadmap with a 45% emissions reduction target from 2020 levels by 2030.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services